Published in Arch Intern Med on July 26, 2010
Overdiagnosis and overtreatment of prostate cancer. Eur Urol (2014) 3.25
Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst (2011) 1.98
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. BMC Med (2014) 1.11
Self-Reported Health Status Predicts Other-Cause Mortality in Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study. J Gen Intern Med (2015) 0.94
The impact of PSA testing frequency on prostate cancer incidence and treatment in older men. Prostate Cancer Prostatic Dis (2011) 0.93
Improving the communication of benefits and harms of treatment strategies: decision AIDS for localized prostate cancer treatment decisions. J Natl Cancer Inst Monogr (2012) 0.91
Active surveillance for prostate cancer: an underutilized opportunity for reducing harm. J Natl Cancer Inst Monogr (2012) 0.90
Management of low (favourable)-risk prostate cancer. BJU Int (2011) 0.84
Predictors of repeated PSA testing among black and white men from the Maryland Cancer Survey, 2006. Prev Chronic Dis (2011) 0.82
The cautionary tale of PSA testing. Arch Intern Med (2010) 0.81
Single high intensity focused ultrasound session as a whole gland primary treatment for clinically localized prostate cancer: 10-year outcomes. Prostate Cancer (2014) 0.80
Treatment Preferences for Active Surveillance versus Active Treatment among Men with Low-Risk Prostate Cancer. Cancer Epidemiol Biomarkers Prev (2016) 0.80
An economic analysis of conservative management versus active treatment for men with localized prostate cancer. J Natl Cancer Inst Monogr (2012) 0.79
Does true Gleason pattern 3 merit its cancer descriptor? Nat Rev Urol (2016) 0.76
Time to rethink PSA screening. Arch Intern Med (2011) 0.76
Prostate cancer detection: a view of the future. Eur Urol (2010) 0.75
Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less. Iran J Public Health (2015) 0.75
Re: Risk Profiles and Treatment Patterns Among Men Diagnosed as Having Prostate Cancer and a Prostate-Specific Antigen Level Below 4.0 ng/ml. J Urol (2011) 0.75
Treatment patterns for older veterans with localized prostate cancer. Cancer Epidemiol (2015) 0.75
PSA: Possible surgery avoidance with use of free PSA. Arch Intern Med (2011) 0.75
Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System. World J Urol (2016) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care (2002) 21.63
Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med (2008) 18.60
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst (2002) 9.45
Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst (2008) 8.62
Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA (2006) 8.16
Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst (2009) 6.96
Quality of life after radical prostatectomy or watchful waiting. N Engl J Med (2002) 6.83
Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA (2008) 5.66
Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst (2006) 5.42
The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol (2004) 5.09
Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era. J Natl Cancer Inst (2007) 3.07
Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol (2001) 2.33
Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst (2005) 2.15
It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer. J Urol (2008) 1.66
Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys (2008) 1.63
Early stage prostate cancer--do we have a problem with over-detection, overtreatment or both? J Urol (2005) 1.46
Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features. Urology (2002) 1.41
Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study. J Urol (2004) 1.34
Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol (2008) 1.33
Health-related quality of life in treatment for prostate cancer: looking beyond survival. Support Cancer Ther (2004) 0.94
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med (2015) 8.80
Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med (2013) 7.95
Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst (2009) 6.07
Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA (2008) 5.66
Outcomes of localized prostate cancer following conservative management. JAMA (2009) 5.57
The double-edged sword of autophagy modulation in cancer. Clin Cancer Res (2009) 5.46
Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res (2011) 5.40
Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol (2008) 4.72
Trends in Metastatic Breast and Prostate Cancer--Lessons in Cancer Dynamics. N Engl J Med (2015) 4.58
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Prostate specific antigen best practice statement: 2009 update. J Urol (2009) 3.95
Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst (2013) 3.81
Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med (2013) 3.74
Tumorigenic effect of some commonly used moisturizing creams when applied topically to UVB-pretreated high-risk mice. J Invest Dermatol (2008) 3.44
Active surveillance for early-stage prostate cancer: review of the current literature. Cancer (2008) 3.18
Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer (2002) 3.05
Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol (2009) 2.95
Contemporary risk profile of prostate cancer in the United States. J Natl Cancer Inst (2009) 2.85
5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol (2005) 2.72
Late gastrointestinal toxicities following radiation therapy for prostate cancer. Eur Urol (2011) 2.69
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2004) 2.65
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
Metabolic catastrophe as a means to cancer cell death. J Cell Sci (2007) 2.58
Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst (2002) 2.54
Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol (2011) 2.53
5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol (2008) 2.16
Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4alpha gene. Hepatology (2008) 2.12
Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications. BJU Int (2013) 2.10
A mixture model for estimating the local false discovery rate in DNA microarray analysis. Bioinformatics (2004) 2.03
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol (2004) 2.02
Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens (2006) 1.95
General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. J Clin Oncol (2003) 1.91
Differential regulation of interleukin 1 receptor and Toll-like receptor signaling by MEKK3. Nat Immunol (2003) 1.88
Analyzing excessive no changes in clinical trials with clustered data. Biometrics (2004) 1.87
Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother Oncol (2011) 1.75
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol (2007) 1.75
The role of the death-domain kinase RIP in tumour-necrosis-factor-induced activation of mitogen-activated protein kinases. EMBO Rep (2003) 1.73
United States radiation oncologists' and urologists' opinions about screening and treatment of prostate cancer vary by region. Urology (2002) 1.73
Inhibition of intestinal tumorigenesis in Apcmin/+ mice by (-)-epigallocatechin-3-gallate, the major catechin in green tea. Cancer Res (2005) 1.72
Risk-based prostate cancer screening. Eur Urol (2011) 1.64
Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer (2008) 1.63
Timing of curative treatment for prostate cancer: a systematic review. Eur Urol (2013) 1.63
Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group. Clin Cancer Res (2006) 1.60
Tumor necrosis factor and cancer, buddies or foes? Acta Pharmacol Sin (2008) 1.60
Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU Int (2010) 1.57
Heart rate variability biofeedback increases baroreflex gain and peak expiratory flow. Psychosom Med (2003) 1.55
Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer? Eur Urol (2012) 1.55
The death domain kinase RIP has an essential role in DNA damage-induced NF-kappa B activation. Genes Dev (2003) 1.54
Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol (2006) 1.54
Quantitative assessment of AKAP12 promoter methylation in colorectal cancer using methylation-sensitive high resolution melting: Correlation with Duke's stage. Cancer Biol Ther (2010) 1.50
PC-SPES: herbal formulation for prostate cancer. Urology (2002) 1.48
MUC1 in macrophage: contributions to cigarette smoke-induced lung cancer. Cancer Res (2013) 1.48
A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A (2004) 1.47
Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer. J Clin Oncol (2005) 1.45
Essential roles of receptor-interacting protein and TRAF2 in oxidative stress-induced cell death. Mol Cell Biol (2004) 1.43
Clinical and biological activity of soy protein powder supplementation in healthy male volunteers. Cancer Epidemiol Biomarkers Prev (2007) 1.43
Activator protein-1 transcription factors are associated with progression and recurrence of prostate cancer. Cancer Res (2008) 1.42
Stomatocytosis heralding a case of acute Wilsonian crisis. Ann Hematol (2009) 1.41
A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol (2012) 1.41
Autophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibition. PLoS One (2012) 1.37
17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway. Cancer Res (2006) 1.36
Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis. Cancer J (2003) 1.35
Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells. Carcinogenesis (2007) 1.33
Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era. J Urol (2008) 1.33
A critical role of luteolin-induced reactive oxygen species in blockage of tumor necrosis factor-activated nuclear factor-kappaB pathway and sensitization of apoptosis in lung cancer cells. Mol Pharmacol (2007) 1.23
Caffeine and caffeine sodium benzoate have a sunscreen effect, enhance UVB-induced apoptosis, and inhibit UVB-induced skin carcinogenesis in SKH-1 mice. Carcinogenesis (2006) 1.22
Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Mol Cancer Ther (2008) 1.22
A genotyping system capable of simultaneously analyzing >1000 single nucleotide polymorphisms in a haploid genome. Genome Res (2005) 1.21
Strong correlation between meiotic crossovers and haplotype structure in a 2.5-Mb region on the long arm of chromosome 21. Genome Res (2005) 1.20
NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target. Front Biosci (Landmark Ed) (2011) 1.19
Expression genomics of cervical cancer: molecular classification and prediction of radiotherapy response by DNA microarray. Clin Cancer Res (2003) 1.19
Acquired activation of the Akt/cyclooxygenase-2/Mcl-1 pathway renders lung cancer cells resistant to apoptosis. Mol Pharmacol (2009) 1.18
Multistage genome-wide association meta-analyses identified two new loci for bone mineral density. Hum Mol Genet (2013) 1.17
Differential temporal expression of matrix metalloproteinases after spinal cord injury: relationship to revascularization and wound healing. J Neurosurg (2003) 1.17
Patterns and correlates of prostate cancer treatment in older men. Am J Med (2011) 1.17
Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res (2002) 1.16
The population level prevalence and correlates of appropriate and inappropriate imaging to stage incident prostate cancer in the medicare population. J Urol (2011) 1.16
PSA testing: public policy or private penchant? JAMA (2006) 1.14
Rapid detection and curation of conserved DNA via enhanced-BLAT and EvoPrinterHD analysis. BMC Genomics (2008) 1.14
Stimulatory effect of topical application of caffeine on UVB-induced apoptosis in mouse skin. Oncol Res (2002) 1.14
Analysis of pilot and early phase studies with small sample sizes. Stat Med (2004) 1.13